Managing food allergies comes down to three things: avoiding your triggers, being prepared for accidental exposures, and exploring newer treatments that can raise your tolerance threshold. There’s no cure yet, but the options available today are significantly better than they were even five years ago, with the first injectable medication approved specifically for food allergies in 2024 and oral immunotherapy now available for peanut allergy.
Avoidance and Label Reading
Strict avoidance of your allergen remains the foundation of food allergy management. That sounds simple, but in practice it requires reading every ingredient label, asking detailed questions at restaurants, and learning the less obvious names your allergen can hide behind (casein for milk, albumin for egg, and so on). In the U.S., manufacturers must label for nine major allergens: milk, eggs, peanuts, tree nuts, wheat, soy, fish, shellfish, and sesame.
What labels can’t always tell you is whether a food was made on shared equipment or in a shared facility. Precautionary phrases like “may contain” are voluntary in the U.S., and there’s no standard threshold behind them. To give some sense of scale, the amount of peanut protein predicted to trigger a reaction in 5% of peanut-allergic people is just 3.9 milligrams, roughly a tiny fragment of a single peanut. For egg, it’s even lower at 2.4 milligrams of protein. These numbers explain why even trace contamination matters and why “just a little bit” isn’t safe for many people.
Epinephrine: The Non-Negotiable Safety Net
If you have a food allergy that carries any risk of anaphylaxis, carrying an epinephrine auto-injector everywhere is the single most important thing you can do. Epinephrine is the only first-line treatment for anaphylaxis. Antihistamines can help with mild symptoms like hives or itching, but they cannot stop a severe reaction involving breathing difficulty, throat swelling, or a drop in blood pressure.
After using epinephrine, current guidelines recommend being monitored for four to six hours. The reason is biphasic reactions, where symptoms return after initially improving. In pediatric studies, about 3.4% of children who had anaphylaxis experienced a second wave of symptoms. That percentage is small, but the consequences of a biphasic reaction without medical oversight can be serious. Always call emergency services after injecting epinephrine, even if you feel better quickly.
Oral Immunotherapy for Peanut Allergy
Oral immunotherapy (OIT) involves eating tiny, carefully measured amounts of your allergen daily, with the dose gradually increasing over months under medical supervision. The goal isn’t to let you eat peanut butter sandwiches freely. It’s to raise your threshold high enough that an accidental exposure to a small amount won’t trigger a dangerous reaction.
The first FDA-approved OIT product for peanut allergy is designed for children ages 1 to 17. In clinical trials, about 50 to 68% of treated children could tolerate a dose of roughly 1,000 milligrams of peanut protein (about three peanuts) after treatment, compared to just 2 to 4% of children on placebo. The maintenance dose is 300 milligrams of peanut protein taken daily, and you have to keep taking it to maintain the protection.
The tradeoff is side effects. The most common reactions during the dose-increase phase include stomach pain, nausea, vomiting, hives, and coughing. Younger children (ages 1 to 3) tend to experience these more frequently. Some families find the side effects manageable; others decide to stop treatment. OIT also requires a significant time commitment, with frequent clinic visits during the months-long escalation phase.
Sublingual Immunotherapy: A Gentler Alternative
Sublingual immunotherapy (SLIT) works on the same principle as OIT but uses much smaller doses placed under the tongue rather than swallowed. The allergen is absorbed through the tissue under the tongue, which tends to produce fewer and milder side effects. For people who can’t tolerate the gastrointestinal symptoms of OIT, SLIT offers a less aggressive path.
The tradeoff is lower efficacy. In head-to-head comparisons for peanut allergy, children on OIT were three times more likely to pass a food challenge after one year of treatment (70%) than those on SLIT (30%). For milk allergy, OIT raised tolerance thresholds 54 to 159 times above baseline, while SLIT achieved a 40-fold increase. The overall rate of reactions during treatment is similar between the two approaches, but OIT reactions are more likely to involve multiple body systems and require medication to manage. SLIT reactions tend to stay localized to the mouth.
Omalizumab: A New Injectable Option
In early 2024, the FDA approved omalizumab (originally developed for severe asthma) as the first injectable treatment for food allergy. It works by blocking the antibody that drives allergic reactions, effectively raising the amount of allergen your body can encounter before reacting. It’s approved for adults and children aged 1 and older with one or more food allergies, and it’s given as an injection every two to four weeks.
What makes this treatment distinctive is that it works across multiple food allergies simultaneously. If you’re allergic to peanuts, milk, and eggs, a single treatment addresses all three. Most immunotherapy approaches target one allergen at a time. The key limitation: omalizumab does not replace avoidance. You still need to stay away from your allergens. The treatment is designed to reduce the severity of reactions from accidental exposures, including the risk of anaphylaxis.
Early Introduction to Prevent Allergies
If you’re a parent of an infant, one of the most impactful things you can do is introduce allergenic foods early. National guidelines recommend that babies with severe eczema, egg allergy, or both should be given age-appropriate peanut-containing foods as early as 4 to 6 months of age. This recommendation came from landmark research showing that early exposure dramatically reduces the chance of developing peanut allergy compared to avoidance.
For high-risk infants, an allergist may do a skin prick test or blood test first. If the results fall below certain thresholds, parents can introduce peanut foods at home. Peanut puffs or thinned peanut butter mixed into purees work well for young babies. For infants without eczema or existing food allergies, introducing peanut and other common allergens around 6 months, when they start solids, is generally recommended. The old advice to delay allergenic foods until age 2 or 3 has been firmly reversed.
Better Diagnosis With Component Testing
Standard allergy blood tests measure your overall immune response to a whole food, but that can produce misleading results. You might test positive for peanut because your body reacts to a protein that’s similar to one found in birch pollen, not because you’d actually react to eating peanuts. Component-resolved diagnostics can distinguish between these scenarios by testing your response to specific individual proteins within a food.
For peanut allergy, one particular protein component is the strongest predictor of true clinical allergy and tends to correlate with more severe reactions. Interestingly, the pattern of which proteins trigger reactions varies by geography. American patients more often react to proteins associated with severe symptoms, while patients in Spain and Sweden tend to react to different components linked to milder or cross-reactive responses. For hazelnut allergy, two specific protein components are highly specific markers for genuine allergy with objective symptoms in both children and adults. If you’ve had ambiguous allergy test results, or if you’re unsure whether a positive test means you’d truly react to eating the food, component testing through your allergist can provide much more useful answers.
A Peanut Patch for Toddlers
For children ages 1 to 3, a peanut patch delivering allergen through the skin is showing strong results in clinical trials. In a phase 3 trial published in the New England Journal of Medicine, 67% of toddlers using the patch for 12 months showed a meaningful increase in the amount of peanut they could tolerate, compared to 33.5% on placebo. The patch is worn daily on the skin, which makes it easier to use than daily oral dosing for very young children. It hasn’t received FDA approval yet, but it addresses an important gap since no oral immunotherapy product is currently available for children under 4.